ALK will also pay up to $320m in milestone payments to ARS in the deal, which sees the latter keep rights in the US, ...

The global oral controlled release drug delivery technology market is on track for significant expansion, with projections estimating its market value to soar from USD 34.1 billion in 2022 to USD 68.4 ...

A new focus on dermatology, ophthalmology, and gastroenterology will pave ways for many untapped opportunities that Viatris can utilize with its scale and manufacturing power. We believe Viatris is in ...

Viatris (VTRS) stock surges after Q3 earnings beat expectations with strong revenue growth and optimistic revenue outlook for ...

Drugmaker Viatris beat Wall Street estimates for third-quarter profit and revenue on Thursday, helped by strong demand for its new generic asthma and ADHD drugs, among others, sending its shares up 2.